Background:

The prevalence of obesity is increasing, and as sibutramine is more prescribed, it requires a better understanding of its effects on blood pressure, through a systematic review of all eligible studies.

Objectives:

the aim this review is to assess the influence of the use of sibutramine in obese patients with or without antihypertensive drugs.

Search strategy:

The studies will be identified from the following sources: LILACS, MEDLINE, Cochrane reviews, manual searches, personal communication, contact with pharmaceutical industry. There are no limits about language, date, or other restrictions.

Selection criteria:

types of studies: all studies must be randomized controlled trials using the criteria described in the Cochrane Handbook, adequacy of allocation concealment: types A and B.

Types of interventions: sibutramine compared with placebo. Types of outcome measures: systolic and diastolic blood pressure.

Data collection &

analysis:

two reviewers will independently screen the abstracts of all publications, obtained by the search strategy. Quality assessment: methodological quality of the trials included in this review will be assessed using the criteria described in the Cochrane Handbook (Clarke, 2002).

Reviewers

conclusions:

The sibutramine doesnt affect the blood pressure of obese patient.